CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 17, 2021
Result type: Reports
Project Number: SR0681-000
Product Line: Reimbursement Review

Generic Name: inclisiran

Brand Name: TBC

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Primary hypercholesterolemia

Indications: Inclisiran is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial), as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Manufacturer Requested Reimbursement Criteria1: As an adjunct to diet and maximally tolerated statin (MTS) therapy with or without other lipid‐lowering therapies (LLT) in adults with heterozygous familial hypercholesterolemia (HeFH) or patients who have had prior cardiovascular (CV) events and require additional lowering of LDL‐C.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: February 17, 2021

Call for patient/clinician input closed: April 9, 2021

Anticipated Date: March 17, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback